Mechanisms linking obesity to hypertension

Obesity Reviews

Volumn 13, Issue 1, 2012, Pages 17-26

  Dorresteijn, J A N ^a   Visseren, F L J ^a   Spiering, W ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Hypertension; Metabolic syndrome; Obesity; Obesity related hypertension

Indexed keywords

ADIPONECTIN; ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANTIHYPERTENSIVE AGENT; COLONY STIMULATING FACTOR 1; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FATTY ACID; INSULIN; INTERLEUKIN 6; LEPTIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RESISTIN; THIAZOLIDINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ADIPOSE TISSUE; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CELL INFILTRATION; CELL PROLIFERATION; CEREBROSPINAL FLUID ANALYSIS; CLINICAL PRACTICE; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERLEPTINEMIA; HYPERTENSION; HYPOTHALAMUS; LIFESTYLE MODIFICATION; MACROPHAGE; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SMOOTH MUSCLE FIBER; SYMPATHETIC NERVE; VASCULAR RESISTANCE; VASCULITIS;

ADIPOCYTES; ANTIHYPERTENSIVE AGENTS; HEALTH BEHAVIOR; HUMANS; HYPERTENSION; LIFE STYLE; OBESITY; OXIDATIVE STRESS; RENIN-ANGIOTENSIN SYSTEM; WEIGHT LOSS;

EID: 83855164132     PISSN: 14677881     EISSN: 1467789X     Source Type: Journal    
DOI: 10.1111/j.1467-789X.2011.00914.x     Document Type: Review

References (113)

1. Narkiewicz K. Diagnosis and management of hypertension in obesity. Obes Rev 2006; 7: 155-162.
2. Kotchen TA. Obesity-related hypertension: epidemiology, pathophysiology, and clinical management. Am J Hypertens 2010; 23: 1170-1178.
3. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G etal. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28: 1462-1536.
4. Chen J, Gu D, Huang J, Rao DC, Jaquish CE, Hixson JE etal. Metabolic syndrome and salt sensitivity of blood pressure in non-diabetic people in China: a dietary intervention study. Lancet 2009; 373: 829-835.
5. Pimenta E, Gaddam KK, Oparil S, Aban I, Husain S, Dell'Italia LJ etal. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension 2009; 54: 475-481.
6. Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2003; 42: 878-884.
7. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD etal. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117: e510-e526.
8. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010; 303: 235-241.
9. Nguyen NT, Magno CP, Lane KT, Hinojosa MW, Lane JS. Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity: findings from the National Health and Nutrition Examination Survey, 1999 to 2004. J Am Coll Surg 2008; 207: 928-934.
10. Garrison RJ, Kannel WB, Stokes J 3rd, Castelli WP. Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med 1987; 16: 235-251.
11. Timpson NJ, Harbord R, Davey Smith G, Zacho J, Tybjaerg-Hansen A, Nordestgaard BG. Does greater adiposity increase blood pressure and hypertension risk?: Mendelian randomization using the FTO/MC4R genotype. Hypertension 2009; 54: 84-90.
12. Brown CD, Higgins M, Donato KA, Rohde FC, Garrison R, Obarzanek E etal. Body mass index and the prevalence of hypertension and dyslipidemia. Obes Res 2000; 8: 605-619.
13. Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW etal. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004; 350: 2362-2374.
14. Lee CM, Huxley RR, Wildman RP, Woodward M. Indices of abdominal obesity are better discriminators of cardiovascular risk factors than BMI: a meta-analysis. J Clin Epidemiol 2008; 61: 646-653.
15. Cassano PA, Segal MR, Vokonas PS, Weiss ST. Body fat distribution, blood pressure, and hypertension. A prospective cohort study of men in the normative aging study. Ann Epidemiol 1990; 1: 33-48.
16. De Marco M, de Simone G, Roman MJ, Chinali M, Lee ET, Russell M etal. Cardiovascular and metabolic predictors of progression of prehypertension into hypertension: the Strong Heart Study. Hypertension 2009; 54: 974-980.
17. Tomiyama H, Matsumoto C, Yamada J, Yoshida M, Odaira M, Shiina K etal. Predictors of progression from prehypertension to hypertension in Japanese men. Am J Hypertens 2009; 22: 630-636.
18. Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet 2001; 358: 1682-1686.
19. Droyvold WB, Midthjell K, Nilsen TI, Holmen J. Change in body mass index and its impact on blood pressure: a prospective population study. Int J Obes (Lond) 2005; 29: 650-655.
20. Dall'Asta C, Vedani P, Manunta P, Pizzocri P, Marchi M, Paganelli M etal. Effect of weight loss through laparoscopic gastric banding on blood pressure, plasma renin activity and aldosterone levels in morbid obesity. Nutr Metab Cardiovasc Dis 2009; 19: 110-114.
21. Hajer GR, van Haeften TW, Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J 2008; 29: 2959-2971.
22. Myers MG, Cowley MA, Munzberg H. Mechanisms of leptin action and leptin resistance. Annu Rev Physiol 2008; 70: 537-556.
23. Engeli S, Bohnke J, Gorzelniak K, Janke J, Schling P, Bader M etal. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005; 45: 356-362.
24. Thatcher S, Yiannikouris F, Gupte M, Cassis L. The adipose renin-angiotensin system: role in cardiovascular disease. Mol Cell Endocrinol 2009; 302: 111-117.
25. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-1808.
26. Wang ZV, Scherer PE. Adiponectin, cardiovascular function, and hypertension. Hypertension 2008; 51: 8-14.
27. Ouchi N, Ohishi M, Kihara S, Funahashi T, Nakamura T, Nagaretani H etal. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 2003; 42: 231-234.
28. Cao Y, Tao L, Yuan Y, Jiao X, Lau WB, Wang Y etal. Endothelial dysfunction in adiponectin deficiency and its mechanisms involved. J Mol Cell Cardiol 2009; 46: 413-419.
29. Matsuda M, Shimomura I, Sata M, Arita Y, Nishida M, Maeda N etal. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 2002; 277: 37487-37491.
30. Ouedraogo R, Gong Y, Berzins B, Wu X, Mahadev K, Hough K etal. Adiponectin deficiency increases leukocyte-endothelium interactions via upregulation of endothelial cell adhesion molecules in vivo. J Clin Invest 2007; 117: 1718-1726.
31. Tan KC, Xu A, Chow WS, Lam MC, Ai VH, Tam SC etal. Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. J Clin Endocrinol Metab 2004; 89: 765-769.
32. Kim F, Tysseling KA, Rice J, Pham M, Haji L, Gallis BM etal. Free fatty acid impairment of nitric oxide production in endothelial cells is mediated by IKKbeta. Arterioscler Thromb Vasc Biol 2005; 25: 989-994.
33. Steinberg HO, Paradisi G, Hook G, Crowder K, Cronin J, Baron AD. Free fatty acid elevation impairs insulin-mediated vasodilation and nitric oxide production. Diabetes 2000; 49: 1231-1238.
34. Chen C, Jiang J, Lu JM, Chai H, Wang X, Lin PH etal. Resistin decreases expression of endothelial nitric oxide synthase through oxidative stress in human coronary artery endothelial cells. Am J Physiol Heart Circ Physiol 2010; 299: H193-H201.
35. Verma S, Li SH, Wang CH, Fedak PW, Li RK, Weisel RD etal. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 2003; 108: 736-740.
36. Vlasova M, Purhonen AK, Jarvelin MR, Rodilla E, Pascual J, Herzig KH. Role of adipokines in obesity-associated hypertension. Acta Physiol (Oxf) 2010; 200: 107-127.
37. Azuma K, Katsukawa F, Oguchi S, Murata M, Yamazaki H, Shimada A etal. Correlation between serum resistin level and adiposity in obese individuals. Obes Res 2003; 11: 997-1001.
38. Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV etal. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 2001; 50: 2199-2202.
39. Pou KM, Massaro JM, Hoffmann U, Vasan RS, Maurovich-Horvat P, Larson MG etal. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study. Circulation 2007; 116: 1234-1241.
40. Faber DR, van der Graaf Y, Westerink J, Visseren FL. Increased visceral adipose tissue mass is associated with increased C-reactive protein in patients with manifest vascular diseases. Atherosclerosis 2010; 212: 274-280.
41. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y etal. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004; 114: 1752-1761.
42. Gletsu-Miller N, Hansen JM, Jones DP, Go YM, Torres WE, Ziegler TR etal. Loss of total and visceral adipose tissue mass predicts decreases in oxidative stress after weight-loss surgery. Obesity (Silver Spring) 2009; 17: 439-446.
43. Schnabel R, Larson MG, Dupuis J, Lunetta KL, Lipinska I, Meigs JB etal. Relations of inflammatory biomarkers and common genetic variants with arterial stiffness and wave reflection. Hypertension 2008; 51: 1651-1657.
44. Chae CU, Lee RT, Rifai N, Ridker PM. Blood pressure and inflammation in apparently healthy men. Hypertension 2001; 38: 399-403.
45. Sprague AH, Khalil RA. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol 2009; 78: 539-552.
46. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843.
47. Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007; 56: 1010-1013.
48. Cancello R, Tordjman J, Poitou C, Guilhem G, Bouillot JL, Hugol D etal. Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. Diabetes 2006; 55: 1554-1561.
49. Kawanami D, Maemura K, Takeda N, Harada T, Nojiri T, Imai Y etal. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun 2004; 314: 415-419.
50. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H etal. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000; 102: 1296-1301.
51. Umemura S, Nyui N, Tamura K, Hibi K, Yamaguchi S, Nakamaru M etal. Plasma angiotensinogen concentrations in obese patients. Am J Hypertens 1997; 10: 629-633.
52. Goodfriend TL, Kelley DE, Goodpaster BH, Winters SJ. Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women. Obes Res 1999; 7: 355-362.
53. Saiki A, Ohira M, Endo K, Koide N, Oyama T, Murano T etal. Circulating angiotensin II is associated with body fat accumulation and insulin resistance in obese subjects with type 2 diabetes mellitus. Metabolism 2009; 58: 708-713.
54. Okada S, Kozuka C, Masuzaki H, Yasue S, Ishii-Yonemoto T, Tanaka T etal. Adipose tissue-specific dysregulation of angiotensinogen by oxidative stress in obesity. Metabolism 2010; 59: 1241-1251.
55. Massiera F, Bloch-Faure M, Ceiler D, Murakami K, Fukamizu A, Gasc JM etal. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J 2001; 15: 2727-2729.
56. Yasue S, Masuzaki H, Okada S, Ishii T, Kozuka C, Tanaka T etal. Adipose tissue-specific regulation of angiotensinogen in obese humans and mice: impact of nutritional status and adipocyte hypertrophy. Am J Hypertens 2010; 23: 425-431.
57. Frederich RC Jr, Kahn BB, Peach MJ, Flier JS. Tissue-specific nutritional regulation of angiotensinogen in adipose tissue. Hypertension 1992; 19: 339-344.
58. Ingelsson E, Pencina MJ, Tofler GH, Benjamin EJ, Lanier KJ, Jacques PF etal. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study. Circulation 2007; 116: 984-992.
59. de Paula RB, da Silva AA, Hall JE. Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension 2004; 43: 41-47.
60. Petrasek D, Jensen G, Tuck M, Stern N. In vitro effects of insulin on aldosterone production in rat zona glomerulosa cells. Life Sci 1992; 50: 1781-1787.
61. Colussi G, Catena C, Lapenna R, Nadalini E, Chiuch A, Sechi LA. Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients. Diabetes Care 2007; 30: 2349-2354.
62. Goodfriend TL, Ball DL, Egan BM, Campbell WB, Nithipatikom K. Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension 2004; 43: 358-363.
63. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, Langenbach J, Willenberg HS, Barthel A etal. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A 2003; 100: 14211-14216.
64. Bentley-Lewis R, Adler GK, Perlstein T, Seely EW, Hopkins PN, Williams GH etal. Body mass index predicts aldosterone production in normotensive adults on a high-salt diet. J Clin Endocrinol Metab 2007; 92: 4472-4475.
65. Wada T, Ohshima S, Fujisawa E, Koya D, Tsuneki H, Sasaoka T. Aldosterone inhibits insulin-induced glucose uptake by degradation of insulin receptor substrate (IRS) 1 and IRS2 via a reactive oxygen species-mediated pathway in 3T3-L1 adipocytes. Endocrinology 2009; 150: 1662-1669.
66. Grassi G, Seravalle G, Cattaneo BM, Bolla GB, Lanfranchi A, Colombo M etal. Sympathetic activation in obese normotensive subjects. Hypertension 1995; 25: 560-563.
67. Straznicky NE, Lambert EA, Lambert GW, Masuo K, Esler MD, Nestel PJ. Effects of dietary weight loss on sympathetic activity and cardiac risk factors associated with the metabolic syndrome. J Clin Endocrinol Metab 2005; 90: 5998-6005.
68. Kassab S, Kato T, Wilkins FC, Chen R, Hall JE, Granger JP. Renal denervation attenuates the sodium retention and hypertension associated with obesity. Hypertension 1995; 25: 893-897.
69. Grassi G, Dell'Oro R, Facchini A, Quarti Trevano F, Bolla GB, Mancia G. Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives. J Hypertens 2004; 22: 2363-2369.
70. Tank J, Heusser K, Diedrich A, Hering D, Luft FC, Busjahn A etal. Influences of gender on the interaction between sympathetic nerve traffic and central adiposity. J Clin Endocrinol Metab 2008; 93: 4974-4978.
71. Huggett RJ, Burns J, Mackintosh AF, Mary DA. Sympathetic neural activation in nondiabetic metabolic syndrome and its further augmentation by hypertension. Hypertension 2004; 44: 847-852.
72. Rumantir MS, Vaz M, Jennings GL, Collier G, Kaye DM, Seals DR etal. Neural mechanisms in human obesity-related hypertension. J Hypertens 1999; 17: 1125-1133.
73. Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Mott DM, Bennett PH. Insulin and hypertension. Relationship to obesity and glucose intolerance in Pima Indians. Diabetes 1990; 39: 1430-1435.
74. Weyer C, Pratley RE, Snitker S, Spraul M, Ravussin E, Tataranni PA. Ethnic differences in insulinemia and sympathetic tone as links between obesity and blood pressure. Hypertension 2000; 36: 531-537.
75. Kos K, Harte AL, da Silva NF, Tonchev A, Chaldakov G, James S etal. Adiponectin and resistin in human cerebrospinal fluid and expression of adiponectin receptors in the human hypothalamus. J Clin Endocrinol Metab 2007; 92: 1129-1136.
76. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR etal. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334: 292-295.
77. Rahmouni K, Morgan DA, Morgan GM, Mark AL, Haynes WG. Role of selective leptin resistance in diet-induced obesity hypertension. Diabetes 2005; 54: 2012-2018.
78. Greenfield JR, Miller JW, Keogh JM, Henning E, Satterwhite JH, Cameron GS etal. Modulation of blood pressure by central melanocortinergic pathways. N Engl J Med 2009; 360: 44-52.
79. da Silva AA, do Carmo JM, Kanyicska B, Dubinion J, Brandon E, Hall JE. Endogenous melanocortin system activity contributes to the elevated arterial pressure in spontaneously hypertensive rats. Hypertension 2008; 51: 884-890.
80. Harlan SM, Morgan DA, Agassandian K, Guo DF, Cassell MD, Sigmund CD etal. Ablation of the leptin receptor in the hypothalamic arcuate nucleus abrogates leptin-induced sympathetic activation. Circ Res 2011; 108: 808-812.
81. Lin Y, Matsumura K, Fukuhara M, Kagiyama S, Fujii K, Iida M. Ghrelin acts at the nucleus of the solitary tract to decrease arterial pressure in rats. Hypertension 2004; 43: 977-982.
82. Matsumura K, Tsuchihashi T, Fujii K, Iida M. Neural regulation of blood pressure by leptin and the related peptides. Regul Pept 2003; 114: 79-86.
83. Muntzel MS, Morgan DA, Mark AL, Johnson AK. Intracerebroventricular insulin produces nonuniform regional increases in sympathetic nerve activity. Am J Physiol 1994; 267: R1350-R1355.
84. Liu J, da Silva AA, Tallam LS, Hall JE. Chronic central nervous system hyperinsulinemia and regulation of arterial pressure and food intake. J Hypertens 2006; 24: 1391-1395.
85. Verma S, Leung YM, Yao L, Battell M, Dumont AS, McNeill JH. Hyperinsulinemia superimposed on insulin resistance does not elevate blood pressure. Am J Hypertens 2001; 14: 429-432.
86. Johansson ME, Andersson IJ, Alexanderson C, Skott O, Holmang A, Bergstrom G. Hyperinsulinemic rats are normotensive but sensitized to angiotensin II. Am J Physiol Regul Integr Comp Physiol 2008; 294: R1240-R1247.
87. Scherrer U, Owlya R, Trueb L. Sympathetic-nerve activity before and after resection of an insulinoma. N Engl J Med 1996; 335: 1240-1242.
88. Matsukawa T, Gotoh E, Minamisawa K, Kihara M, Ueda S, Shionoiri H etal. Effects of intravenous infusions of angiotensin II on muscle sympathetic nerve activity in humans. Am J Physiol 1991; 261: R690-R696.
89. Yoshimoto M, Miki K, Fink GD, King A, Osborn JW. Chronic angiotensin II infusion causes differential responses in regional sympathetic nerve activity in rats. Hypertension 2010; 55: 644-651.
90. Lohmeier TE, Lohmeier JR, Haque A, Hildebrandt DA. Baroreflexes prevent neurally induced sodium retention in angiotensin hypertension. Am J Physiol Regul Integr Comp Physiol 2000; 279: R1437-R1448.
91. Grassi G, Seravalle G, Dell'Oro R, Trevano FQ, Bombelli M, Scopelliti F etal. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 2003; 21: 1761-1769.
92. Hoyda TD, Smith PM, Ferguson AV. Adiponectin acts in the nucleus of the solitary tract to decrease blood pressure by modulating the excitability of neuropeptide Y neurons. Brain Res 2009; 1256: 76-84.
93. Tanida M, Shen J, Horii Y, Matsuda M, Kihara S, Funahashi T etal. Effects of adiponectin on the renal sympathetic nerve activity and blood pressure in rats. Exp Biol Med (Maywood) 2007; 232: 390-397.
94. Heinonen MV, Purhonen AK, Miettinen P, Paakkonen M, Pirinen E, Alhava E etal. Apelin, orexin-A and leptin plasma levels in morbid obesity and effect of gastric banding. Regul Pept 2005; 130: 7-13.
95. Zhang Q, Yao F, Raizada MK, O'Rourke ST, Sun C. Apelin gene transfer into the rostral ventrolateral medulla induces chronic blood pressure elevation in normotensive rats. Circ Res 2009; 104: 1421-1428.
96. Ashley EA, Powers J, Chen M, Kundu R, Finsterbach T, Caffarelli A etal. The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc Res 2005; 65: 73-82.
97. Higuchi K, Masaki T, Gotoh K, Chiba S, Katsuragi I, Tanaka K etal. Apelin, an APJ receptor ligand, regulates body adiposity and favors the messenger ribonucleic acid expression of uncoupling proteins in mice. Endocrinology 2007; 148: 2690-2697.
98. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL etal. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
99. He FJ, MacGregor GA. Effect of longer-term modest salt reduction on blood pressure. Cochrane Database Syst Rev 2004; (3): CD004937.
100. Kraschnewski JL, Boan J, Esposito J, Sherwood NE, Lehman EB, Kephart DK etal. Long-term weight loss maintenance in the United States. Int J Obes (Lond) 2010; 34: 1644-1654.
101. Sjostrom L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B etal. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351: 2683-2693.
102. Torgerson JS, Hauptman J, Boldrin MN, Xe SL. Nical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155-161.
103. Scholze J, Grimm E, Herrmann D, Unger T, Kintscher U. Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study. Circulation 2007; 115: 1991-1998.
104. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006; 295: 761-775.
105. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389-1397.
106. Jansen PM, Danser JA, Spiering W, van den Meiracker AH. Drug mechanisms to help in managing resistant hypertension in obesity. Curr Hypertens Rep 2010; 12: 220-225.
107. Jordan J, Engeli S, Boye SW, Le Breton S, Keefe DL. Direct Renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 2007; 49: 1047-1055.
108. Schmieder RE, Philipp T, Guerediaga J, Gorostidi M, Bush C, Keefe DL. Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial. J Hypertens 2009; 27: 1493-1501.
109. Biaggioni I. Should we target the sympathetic nervous system in the treatment of obesity-associated hypertension? Hypertension 2008; 51: 168-171.
110. Sanjuliani AF, de Abreu VG, Francischetti EA. Selective imidazoline agonist moxonidine in obese hypertensive patients. Int J Clin Pract 2006; 60: 621-629.
111. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376: 1903-1909.
112. Lohmeier TE, Iliescu R. Chronic lowering of blood pressure by carotid baroreflex activation: mechanisms and potential for hypertension therapy. Hypertension 2011; 57: 880-886.
113. Phillips SA, Kung JT. Mechanisms of adiponectin regulation and use as a pharmacological target. Curr Opin Pharmacol 2010; 10: 676-683.